Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter

Biosimilars

Business & Regulation Standards & Regulation

Quick-Fire Q&A: Biosimilars in the US

| Stephanie Sutton | 3 min read

Biosimilars have been available in Europe for years. Is the US still lagging behind?

Manufacture Biosimilars

Towards Better Biosimilar Access

| Maryam Mahdi | 4 min read

Though in theory, biosimilars should help improve medicines access, what challenges still stand in the way of therapeutic equality and equity?

Business & Regulation Profession

Welcome to the Pharma Party

| Maryam Mahdi

Celebrate the people, companies, and innovations had the biggest impact on pharma in the last year.

Business & Regulation Biosimilars

Brace for Biosimilars!

| Jeff Baldetti

One decade behind the EU, biosimilars are arriving in the US. What can we expect? Jeff Baldetti from Cardinal Health has a few ideas.

Manufacture Biosimilars

Driving Down Biosimilar COGS

| Amanda Turner, Khaled Mriziq

To keep biosimilars costs as low as possible, take a good look at your purification and characterization processes.

Business & Regulation Biosimilars

ICER Report Exposes Humira Price Hikes

| Angus Stewart

A new report has exposed a Humira US price hike that dwarfs the rises in the price of other drugs.

Business & Regulation Biosimilars

A Warm Welcome to Biosimilars

| Stephanie Sutton

The FDA has approved just three biosimilars in 2021 – but the approvals could shake up the field as discussions around interchangeability intensify.

Business & Regulation Biosimilars

What Lies Ahead for Biosimilars?

| Stephanie Sutton

Sandoz’s Pierre Bourdage talks to us about biosimilars and how uptake can be boosted.

Business & Regulation Business Practice

Pacesetting Leadership

| Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw shares the experiences that have helped shape her career, and the lessons learned along the way.

Business & Regulation Business Practice

Biosimilars’ 2020 Breakthrough?

| Stephanie Sutton

The FDA has approved its first biosimilar of 2020: Pfizer’s Nyvepria (pegfilgrastim-apgf).


Latest White Papers

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

Characterization of the size and concentration of liposomes

| Contributed by Malvern Panalytical

All White Papers

Sister Publications

You might be interested in our Sister Publications:

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register